30 Jun 2017
June 30, 2017

Ascelia Pharma AB acquires Oncoral Pharma ApS

June 30, 2017

Ascelia Pharma AB acquires Oncoral Pharma ApS and its novel tablet based proprietary formulation of the chemotherapeutic agent, irinotecan, which today is only available as an intravenous infusion product.

Solural Pharma will continue to support Ascelia Pharma with chemistry manufacturing and control services.